Icon Advisers Inc. Co. Sells 9,238 Shares of Bristol Myers Squibb Company $BMY

Icon Advisers Inc. Co. reduced its stake in Bristol Myers Squibb Company (NYSE:BMY) by 32.4% during the third quarter, HoldingsChannel reports. The fund owned 19,262 shares of the biopharmaceutical company’s stock after selling 9,238 shares during the period. Icon Advisers Inc. Co.’s holdings in Bristol Myers Squibb were worth $869,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of BMY. Foster Dykema Cabot & Partners LLC boosted its stake in Bristol Myers Squibb by 55.7% in the 3rd quarter. Foster Dykema Cabot & Partners LLC now owns 1,897 shares of the biopharmaceutical company’s stock worth $84,000 after purchasing an additional 679 shares in the last quarter. Crossmark Global Holdings Inc. increased its stake in Bristol Myers Squibb by 8.1% during the 3rd quarter. Crossmark Global Holdings Inc. now owns 246,488 shares of the biopharmaceutical company’s stock valued at $11,117,000 after purchasing an additional 18,462 shares in the last quarter. Orion Porfolio Solutions LLC raised its holdings in Bristol Myers Squibb by 7.4% in the third quarter. Orion Porfolio Solutions LLC now owns 51,484 shares of the biopharmaceutical company’s stock worth $2,322,000 after buying an additional 3,528 shares during the last quarter. Advisory Alpha LLC lifted its stake in shares of Bristol Myers Squibb by 7.0% in the third quarter. Advisory Alpha LLC now owns 9,634 shares of the biopharmaceutical company’s stock worth $441,000 after buying an additional 633 shares in the last quarter. Finally, IFG Advisory LLC bought a new position in shares of Bristol Myers Squibb in the third quarter worth approximately $2,337,000. 76.41% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on the stock. Truist Financial set a $65.00 price target on shares of Bristol Myers Squibb in a research report on Wednesday, December 3rd. Citigroup upped their price objective on Bristol Myers Squibb from $60.00 to $64.00 and gave the company a “neutral” rating in a research report on Friday, February 6th. Leerink Partners lifted their target price on Bristol Myers Squibb from $54.00 to $60.00 and gave the stock an “outperform” rating in a report on Tuesday, January 13th. Cantor Fitzgerald restated a “neutral” rating on shares of Bristol Myers Squibb in a research note on Monday, November 24th. Finally, Scotiabank reaffirmed a “sector perform” rating and set a $60.00 price objective (up from $53.00) on shares of Bristol Myers Squibb in a research report on Friday, January 9th. Nine analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Bristol Myers Squibb currently has a consensus rating of “Hold” and a consensus price target of $61.00.

Bristol Myers Squibb Trading Down 0.9%

Shares of BMY stock opened at $60.21 on Friday. The company has a current ratio of 1.26, a quick ratio of 1.14 and a debt-to-equity ratio of 2.32. Bristol Myers Squibb Company has a 12-month low of $42.52 and a 12-month high of $63.33. The stock has a market capitalization of $122.62 billion, a P/E ratio of 17.45, a P/E/G ratio of 0.17 and a beta of 0.26. The firm’s 50 day moving average is $57.66 and its 200 day moving average is $50.99.

Bristol Myers Squibb (NYSE:BMY) last announced its earnings results on Thursday, February 5th. The biopharmaceutical company reported $1.26 earnings per share for the quarter, missing analysts’ consensus estimates of $1.65 by ($0.39). The company had revenue of $12.50 billion for the quarter, compared to analysts’ expectations of $12.24 billion. Bristol Myers Squibb had a net margin of 14.64% and a return on equity of 69.65%. Bristol Myers Squibb’s quarterly revenue was up 1.3% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.67 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Research analysts expect that Bristol Myers Squibb Company will post 6.74 earnings per share for the current year.

Bristol Myers Squibb Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, May 1st. Investors of record on Thursday, April 2nd will be given a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a yield of 4.2%. The ex-dividend date is Thursday, April 2nd. Bristol Myers Squibb’s dividend payout ratio is 73.04%.

Key Bristol Myers Squibb News

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: U.S. FDA approved Sotyktu (deucravacitinib) for adults with active psoriatic arthritis — a label expansion that can broaden Sotyktu’s market opportunity and revenue runway. U.S. FDA Approves Bristol Myers Squibb’s Sotyktu® (deucravacitinib) for the Treatment of Adults with Active Psoriatic Arthritis
• Positive Sentiment: BMY declared a quarterly dividend of $0.63/share (ex-dividend April 2), maintaining a high-yield payout that supports income-focused investors and can underpin the stock’s valuation. Dividend Announcement
• Positive Sentiment: Reblozyl showed positive Phase 2 results in alpha-thalassemia and has exceeded $2.3B in annualized sales — evidence Reblozyl is becoming a material growth driver as older drugs decline. Reblozyl Phase 2 Success Shapes Bristol Myers Squibb Valuation Story
• Neutral Sentiment: Bristol-Myers Squibb is tracking the real-world impact of KarXT in schizophrenia — useful clinical/market data but longer-term and unlikely to move near-term earnings. Bristol-Myers Squibb Tracks Real-World Impact of KarXT in Schizophrenia
• Negative Sentiment: Q4 results showed revenue roughly in line but EPS missed consensus (reported $1.26 vs. ~$1.65 expected), which prompted investor selling and weighed on the stock. Earnings and Market Reaction
• Negative Sentiment: Recent articles highlight a larger-than-market intraday decline and analyst focus on legacy-product pressures — shorter-term sentiment and volatility remain a risk until new product growth scales. Bristol Myers Squibb (BMY) Registers a Bigger Fall Than the Market

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.